Physician

Joshua J Mcfarlane, MD

According to 2025 Medicare claims, Joshua Mcfarlane, MD (NPI: 1184847055) practices hematology/oncology in the Richmond, VA market, with the plurality of this provider's patient population coming from Henrico, VA. This provider's primary affiliated billing organization is VIRGINIA CANCER INSTITUTE INCORPORATED (NPI: 1730130980; TIN: 54-1066435) and primary practice location at 23229-8605.

Mcfarlane's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 947 traditional Medicare patients, billed 116,662 HCPCS/CPT codes, and received $2,968,062 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,904 prescription claims across 256 beneficiaries totaling $4,143,221 in drug costs, led by Revlimid (Lenalidomide). DME data shows 81 claims. Open Payments data shows 96 records totaling $3,240. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,816,479 to $2,968,062. Similarly, Part D prescription costs have risen steadily, from $2,185,631 to $4,143,221. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $6,610 to $1,039.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	962	118,432	$1,816,479
2016	1,012	106,830	$1,887,768
2017	1,124	125,937	$2,234,093
2018	1,208	173,004	$2,483,747
2019	1,202	184,045	$3,024,586
2020	1,079	121,666	$2,452,542
2021	1,074	138,262	$2,928,493
2022	1,048	156,426	$2,841,147
2023	985	142,740	$2,617,840
2024	947	116,662	$2,968,062

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	185	1,658	$2,185,631
2016	183	1,638	$2,586,984
2017	200	1,758	$2,944,230
2018	223	1,964	$4,068,838
2019	214	1,898	$4,183,612
2020	205	1,662	$4,203,150
2021	211	1,733	$4,798,084
2022	241	1,668	$4,552,977
2023	225	1,729	$3,820,012
2024	256	1,904	$4,143,221

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	229	$64,228
2016	N/R	255	$68,827
2017	N/R	173	$25,727
2018	N/R	97	$10,083
2019	N/R	49	$4,324
2020	N/R	22	$796
2021	N/R	89	$5,598
2022	N/R	85	$2,795
2023	N/R	82	$14,033
2024	N/R	81	$1,661

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	140	325	$95
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	285	598	$91
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	339	474	$62
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	154	170	$13
96372	Injection of drug or substance under skin or into muscle	142	308	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	58	1,624	$1,028,703
Pomalyst	Pomalidomide	34	952	$770,215
Calquence	Acalabrutinib Maleate	36	1,080	$457,951
Imbruvica	Ibrutinib	28	1,032	$445,059
Ibrance	Palbociclib	23	644	$333,987

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	29	$837
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	30	$565
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	22	$260

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	95	$2,040	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$1,200	Genentech, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Joshua J. Mcfarlane, MD?

Tedicare shows public-source Medicare data for Joshua J. Mcfarlane, MD (NPI 1184847055), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Joshua J. Mcfarlane, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Joshua J. Mcfarlane, MD?

Joshua J. Mcfarlane, MD is linked to VIRGINIA CANCER INSTITUTE INCORPORATED (billing NPI 1730130980) in the available physician profile data.

Does Joshua J. Mcfarlane, MD have Open Payments data?

Joshua J. Mcfarlane, MD has 96 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.